ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Short Communication



Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction

Kevan English, Christine Uwibambe.



Abstract
 Download PDF Cited by 0 ArticlesPost

Obesity is a well-known risk factor for heart failure with preserved ejection fraction (HFpEF). Through recent clinical trials, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been shown to decrease mortality and improve symptoms in patients with obesity and HFpEF. Based on the new existing data, we suggest a change in clinical practice for physicians globally. Evidence now supports the initiation of GLP-1/GIP agonists in patients with obesity and HFpEF. This short communication reviews some of the most recent data on GLP-1/GIP agonists that support their clinical indications for patients with obesity and heart failure.

Key words: Heart failure with preserved ejection fraction; Obesity; Glucagon-like peptide-1 receptor agonists; Systemic inflammation; Glucose-dependent insulinotropic polypeptide

Bibliomed Article Statistics

44
123
20
20
30
35
30
36
R
E
A
D
S

34

24

22

8

17

15

12

23
D
O
W
N
L
O
A
D
S
0708091011120102
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com


ejPort - eJManager.com
Author Tools
 About BiblioMed
License Information
Terms & Conditions
Privacy Policy
 Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.